ShockWave Medical (SWAV)
(Delayed Data from NSDQ)
$329.85 USD
-0.28 (-0.08%)
Updated May 20, 2024 04:00 PM ET
After-Market: $329.85 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Income Statements
Fiscal Year end for ShockWave Medical, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 730 | 490 | 237 | 68 | 43 |
Cost Of Goods | 95 | 65 | 41 | 21 | 17 |
Gross Profit | 635 | 425 | 196 | 47 | 26 |
Selling & Adminstrative & Depr. & Amort Expenses | 476 | 301 | 197 | 112 | 78 |
Income After Depreciation & Amortization | 159 | 124 | -1 | -66 | -52 |
Non-Operating Income | 22 | -1 | -7 | 1 | 2 |
Interest Expense | 7 | 2 | 1 | 1 | 1 |
Pretax Income | 174 | 121 | -9 | -66 | -51 |
Income Taxes | 27 | -95 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 147 | 216 | -9 | -66 | -51 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 147 | 216 | -9 | -66 | -51 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 171 | 130 | 5 | -62 | -49 |
Depreciation & Amortization (Cash Flow) | 12 | 5 | 6 | 4 | 3 |
Income After Depreciation & Amortization | 159 | 124 | -1 | -66 | -52 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 38.21 | 37.88 | 35.10 | 33.09 | 23.91 |
Diluted EPS Before Non-Recurring Items | 3.85 | 5.70 | -0.26 | -1.99 | -2.14 |
Diluted Net EPS (GAAP) | 3.85 | 5.70 | -0.26 | -1.99 | -2.14 |
Fiscal Year end for ShockWave Medical, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 218.81 | 202.98 | 186.02 | 180.17 | 161.07 |
Cost Of Goods | 28.21 | 25.32 | 24.51 | 24.49 | 21.07 |
Gross Profit | 190.60 | 177.66 | 161.51 | 155.67 | 140.00 |
SG&A, R&D, and Dept/Amort Expenses | 148.20 | 134.38 | 117.89 | 123.30 | 100.19 |
Income After SG&A, R&D, and Dept/Amort Expenses | 42.40 | 43.28 | 43.62 | 32.37 | 39.81 |
Non-Operating Income | 10.54 | 15.13 | 3.97 | 1.44 | 1.56 |
Interest Expense | 2.94 | 2.95 | 2.51 | 0.81 | 0.64 |
Pretax Income | 50.00 | 55.46 | 45.08 | 33.00 | 40.74 |
Income Taxes | -5.35 | 11.16 | 10.09 | 4.14 | 1.61 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 55.35 | 44.31 | 34.99 | 28.86 | 39.13 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 55.35 | 44.31 | 34.99 | 28.86 | 39.13 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 38.47 | 38.16 | 38.20 | 38.23 | 37.98 |
Diluted EPS Before Non-Recurring Items | 1.44 | 1.16 | 0.92 | 0.76 | 1.03 |
Diluted Net EPS (GAAP) | 1.44 | 1.14 | 0.92 | 0.76 | 1.03 |